Editing The Genome To Treat MECP2 Duplication Syndrome | Rett Syndrome Research Trust |
|
In this webinar held on January 14, 2021, Ronald Cohn, MD, President and CEO of The Hospital for Sick Children and lab members, Zhenya Ivakine, PhD, and Eleonora Maino present an update on their project for MECP2 Duplication syndrome.
--------------------------------- The Rett Syndrome Research Trust is singularly focused on a cure for Rett syndrome and related MECP2 disorders. Achieving success takes a deep understanding of the relevant science, an environment built for scientific collaboration, and experience with drug and business development. Today we are building on incredible scientific and industry momentum by implementing six genetic-based strategies that tackle Rett from every angle. Every single company pursuing a cure for Rett is able to do so because they leveraged discoveries and resources that were generated with RSRT funding. RSRT is the home of the Rett cure community, and we are confident that together we will cure Rett syndrome. |